Nafamostat

Nafamostat
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate;
CAS Number	81525-10-2 ;
PubChem CID	4413;
IUPHAR/BPS	4262;
ChemSpider	4260 ;
UNII	Y25LQ0H97D;
KEGG	D01670 ;
CompTox Dashboard (EPA)	DTXSID0048420 ;
Chemical and physical data
Formula	C19H17N5O2
Molar mass	347.37 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N;
	InChI InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24) ; Key:MQQNFDZXWVTQEH-UHFFFAOYSA-N ;
(what is this?) (verify)

Nafamostat (INN), a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat is formulated with HCl salt due to its basic tendencies. This is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin.

It is a tryptase inhibitor, which is implicated in leaking blood vessels of dengue haemorrhagic fever and end stage dengue shock syndrome. It is available in generic form already used for the treatment of certain bleeding complications in some countries, but risks of complications (incl anaphylaxis) must be weighed in non-emergency care.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.